Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anagrelide Retard in Essential Thrombocythaemia
NCT01230775Phase 3Completed
- Sponsor
- AOP Health
- Start
- Dec 2010
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of anagrelide in essential thrombocythemia (ET), sponsored by AOP Health. Started Dec 2010; status: completed.
02
Drugs
anagrelide
03
Conditions
essential thrombocythemia (ET)
Beyond the preview
Go deeper on NCT01230775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01230775.